Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Autolus Therapeutics plc AUTL

Healthcare Biotechnology
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy... see more

Recent & Breaking News (NDAQ:AUTL)

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

GlobeNewswire 10 days ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

GlobeNewswire 11 days ago

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

GlobeNewswire April 2, 2024

Autolus Therapeutics Announces Changes to its Board of Directors

GlobeNewswire April 1, 2024

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

GlobeNewswire March 14, 2024

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

GlobeNewswire March 12, 2024

Autolus Therapeutics announces publication in Blood Cancer Journal

GlobeNewswire March 11, 2024

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

GlobeNewswire February 29, 2024

Autolus Therapeutics announces publication in Nature Communications 

GlobeNewswire February 22, 2024

Autolus Announces Pricing of Underwritten Offering

GlobeNewswire February 8, 2024

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  

GlobeNewswire February 8, 2024

Autolus Therapeutics announces publication in ACS Chemical Biology

GlobeNewswire January 23, 2024

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

GlobeNewswire January 22, 2024

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

GlobeNewswire January 10, 2024

Autolus Therapeutics Announces Changes to its Board of Directors

GlobeNewswire December 22, 2023

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

GlobeNewswire December 9, 2023

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

GlobeNewswire November 27, 2023

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

GlobeNewswire November 15, 2023

Autolus Therapeutics announces participation in upcoming conferences

GlobeNewswire November 6, 2023

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

GlobeNewswire November 2, 2023